Diametric Capital’s Sage Therapeutics SAGE Stock Holding History

Diametric Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-39,276	Closed	-$312K	–	384
2025 Q1	$312K	Buy	+39,276	New	+$288K	0.37%	94
2022 Q4	–	Sell	-34,515	Closed	-$1.35M	–	355
2022 Q3	$1.35M	Buy	34,515 +15,122	+78%	+$585K	0.68%	35
2022 Q2	$626K	Buy	+19,393	New	+$650K	0.46%	58

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Diametric Capital's SAGE Position: Q2 2025 in Review

Diametric Capital sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 39,276 shares — an estimated $312K sold.

Diametric Capital first reported a position in SAGE in Q2 2022 and held it in 3 quarters. The position peaked at $1.35M in Q3 2022. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Diametric Capital reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Diametric Capital sold 39,276 Sage Therapeutics shares in Q2 2025, an estimated $312K.
Diametric Capital first reported a position in Sage Therapeutics in Q2 2022 and held it in 3 quarters.
Diametric Capital's Sage Therapeutics position peaked at $1.35M in Q3 2022.
192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Diametric Capital's 13F filing for Q2 2025, filed 13 Aug 2025.